Chia‐Chi Lin

Jang-Ming Lee, Hsiu‐Po Wang, K. Yeh, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of experimental & clinical cancer research : CR.

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

G. Sonpavde, W. Oh, M. Galsky, 2014, Urologic oncology.

Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.

Yih-Leong Chang, Jang-Ming Lee, Chih-Hung Hsu, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

W. Tap, J. Healey, H. Gelderblom, 2020, The Oncologist.

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

A. Tolcher, C. Geyer, C. Takimoto, 2009, Cancer Chemotherapy and Pharmacology.

Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.

Jang-Ming Lee, K. Yeh, Chih-Hung Hsu, 2018, Anticancer research.

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Jih-Hsiang Lee, T. Chen, J. Yang, 2019, Investigational New Drugs.

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

G. Curigliano, Dong-Wan Kim, M. Schuler, 2019, Journal of Clinical Oncology.

Novel Trial Designs for Early Phase Clinical Trials

Chia‐Chi Lin, 2020 .

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Christoph, E. Felip, L. Paz-Ares, 2021 .

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.

E. Felip, L. Paz-Ares, B. Cho, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Should we design clinical trials differently in the era of cancer immunotherapy?

Chia‐Chi Lin, 2019, Journal of Immunotherapy and Precision Oncology.

A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Y. Bang, Chia‐Chi Lin, M. Karasarides, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

G. Abou-Alfa, R. Kelley, T. Yau, 2018, The oncologist.

Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.

D. Nam, Y. Bang, I. Braña, 2014 .

A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma

K. Yeh, Chia‐Chi Lin, A. Cheng, 2018, AntiCancer Research.

Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2022, Esophagus.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

A. Mansfield, G. Curigliano, M. Schuler, 2021, The lancet. Diabetes & endocrinology.

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Jesse S. Voss, B. Goh, R. Smallridge, 2020, Thyroid : official journal of the American Thyroid Association.

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Y. Bang, Y. Im, J. Watanabe, 2021, Clinical Cancer Research.

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

G. Sonpavde, W. Oh, M. Galsky, 2013, Clinical genitourinary cancer.

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

J. Machiels, Y. Bang, A. Italiano, 2021, Clinical Cancer Research.

Active tuberculosis during temsirolimus and bevacizumab treatment.

Y. Pu, Chia‐Chi Lin, Jann-Yuan Wang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

A. Drilon, T. Wilson, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Y. Ando, Chia‐Chi Lin, B. Ma, 2016, Cancer science.

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

J. Esteve, Bernard Pereira, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Huyuan Yang, Y. Bang, Chia‐Chi Lin, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Moving Beyond 3+3: The Future of Clinical Trial Design.

B. Hobbs, R. Kurzrock, D. Hong, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression

A. Zhu, S. Choo, M. Schuler, 2017 .

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.

Yih-Leong Chang, J. Shih, J. Yang, 2017, The Lancet. Respiratory medicine.

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2021, Journal of Cancer Research and Clinical Oncology.

Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors.

G. Shapiro, D. Cho, Chia‐Chi Lin, 2011 .

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.

B. Solomon, Dong-Wan Kim, Geoffrey Liu, 2022, Lung cancer.

An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC.

N. Syn, Dong-Wan Kim, Chia‐Chi Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007, The Journal of urology.

A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

M. Shi, Chia‐Chi Lin, B. Escudier, 2010 .

Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy

Yung‐Chie Lee, Jang-Ming Lee, Y. Tsai, 2009, Annals of Surgical Oncology.

Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors.

Chia‐Chi Lin, 2021, Journal of immunotherapy and precision oncology.

A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.

Chih-Hsin Yang, Chiun Hsu, K. Yeh, 2002, Anticancer research.

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

R. Dziadziuszko, G. Weiss, J. Infante, 2015 .

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Jie Yang, M. Ahn, T. Mok, 2020 .

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Keunchil Park, B. Cho, Sang-We Kim, 2021, JTO clinical and research reports.

Scalp melanoma in a woman with LEOPARD syndrome: possible implication of PTPN11 signaling in melanoma pathogenesis.

Chia‐Chi Lin, Y. Liao, C. Hsiao, 2013, Journal of the American Academy of Dermatology.

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.

Wen-Jeng Wu, Chao-yuan Huang, Chia‐Chi Lin, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

E. Hitre, Chia‐Chi Lin, M. Brose, 2022, Cancer.

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

E. Felip, L. Paz-Ares, B. Cho, 2018 .

First‐Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never‐Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2014, European journal of cancer.

Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.

W. Su, C. Yen, Chia‐Chi Lin, 2020, The oncologist.

Weekly cisplatin plus infusional high‐dose 5‐fluorouracil and leucovorin (P‐HDFL) for metastatic urothelial carcinoma

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2006, Cancer.

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.

J. Shih, J. Yang, Jin-Shing Chen, 2019, European journal of cancer.

Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers.

Kuen-Yuan Chen, Wern-Cherng Cheng, Chia‐Chi Lin, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

K. Venkatakrishnan, Chia‐Chi Lin, B. Ma, 2015, Investigational New Drugs.

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Y. Bang, A. Italiano, A. Patnaik, 2020, Clinical Cancer Research.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A. Tolcher, I. Puzanov, K. Papadopoulos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer

Jih-Hsiang Lee, T. Chen, Y. Chao, 2019 .

Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability

K. Yeh, Chia‐Chi Lin, L. Tseng, 2017 .

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

J. Baselga, Y. Bang, R. Salgia, 2017, BMC Cancer.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

A. Shaw, S. Ou, Gregory Riely, 2018, The Lancet. Oncology.

Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).

Keunchil Park, Y. Bang, F. D. De Braud, 2020, European journal of cancer.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2019, European journal of cancer.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

J. Lunceford, Y. Bang, J. Juco, 2016, The Lancet. Oncology.

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2017, Lung cancer.

Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma.

Chih-Hung Hsu, Chia‐Chi Lin, Min-Shu Hsieh, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

J. Shih, Jin-Shing Chen, Chia‐Chi Lin, 2017, The oncologist.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Journal of Biomedical Science.

PD-1 Blockade in Anaplastic Thyroid Carcinoma

P. Ascierto, R. Ramlau, A. Santoro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

F. Hodi, G. Curigliano, A. Santoro, 2021, Clinical Cancer Research.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

R. Berger, T. Seiwert, R. Mehra, 2016 .

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

J. Yang, Chia‐Chi Lin, A. Cheng, 2019, Targeted Oncology.

Angiokinase inhibitors in non-small-cell lung cancer

J. Yang, Chia‐Chi Lin, Wei-Chen Lu, 2015 .

Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?

Jang-Ming Lee, Chia‐Chi Lin, J. Cheng, 2017, Digestive Surgery.

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations

Chia-Chi Lin, Jih-Hsiang Lee, J. Yang, 2017, Expert review of respiratory medicine.

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.

J. Yang, Chia‐Chi Lin, H. Kao, 2013, Future oncology.

Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations

J. Yang, Chia‐Chi Lin, 2012, Drugs.

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

R. Salgia, P. LoRusso, Yoon-Koo Kang, 2020, Molecular Cancer Therapeutics.

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

R. Dziadziuszko, G. Weiss, W. Su, 2019, British Journal of Cancer.

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

D. Nam, Y. Bang, M. Schuler, 2019, Cancer science.

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2015, Current opinion in oncology.

Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.

Yeun-Chung Chang, Pan‐Chyr Yang, Chih-Hung Hsu, 2008, Lung cancer.

Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2007, Urology.

Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens

Yih-Leong Chang, Jang-Ming Lee, J. Yang, 2022, Cancer medicine.

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

A. Italiano, M. Chiron, Chia‐Chi Lin, 2022, Journal for ImmunoTherapy of Cancer.

Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites

Chih-Hung Hsu, Chia‐Chi Lin, Li‐Chun Lu, 2021, Oncology.

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

A. Italiano, M. Millward, M. Tanner, 2021, Cancer Immunology, Immunotherapy.

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

A. Dechaphunkul, J. Maneechavakajorn, Chia‐Chi Lin, 2020, European journal of cancer.

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

J. Desai, K. Rau, M. Friedlander, 2020, Journal for immunotherapy of cancer.

Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

T. Powles, D. Petrylak, Chia‐Chi Lin, 2020 .

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Chih-Hung Hsu, Chia‐Chi Lin, Y. Shao, 2019, AntiCancer Research.

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2013, Drugs.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

M. Ahn, T. Mok, H. Onishi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Jih-Hsiang Lee, J. Shih, J. Yang, 2020, JTO clinical and research reports.

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2007, Anti-cancer drugs.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Jie Yang, Jih-Hsiang Lee, Chia‐Chi Lin, 2016, Journal of Biomedical Science.

Safety of gefitinib in non-small cell lung cancer treatment

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Expert opinion on drug safety.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Jih-Hsiang Lee, J. Shih, J. Yang, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

R. Medema, J. Yang, Chia‐Chi Lin, 2011, Clinical Cancer Research.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

J. Shih, T. Mok, G. Chen, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer

Chia‐Chi Lin, Chih‐Hsin Yang, 2009, Targeted Oncology.

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Expert review of molecular diagnostics.

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2018, Expert opinion on pharmacotherapy.

Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium

Toshio Shimizu, Dong-Wan Kim, Chia‐Chi Lin, 2021, Asia-Pacific journal of clinical oncology.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

A. Drilon, T. Wilson, C. Chung, 2019, The Lancet. Oncology.

Down-regulated expression of RhoA in human conventional renal cell carcinoma.

C. Shun, Chao-yuan Huang, Y. Pu, 2008, Anticancer research.

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study.

Yih-Leong Chang, Jang-Ming Lee, Jin-Shing Chen, 2019, Clinical lung cancer.

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

G. Pond, G. Sonpavde, W. Oh, 2014, Urologic oncology.

Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.

G. Pond, G. Sonpavde, W. Oh, 2013, Journal of Clinical Oncology.

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

A. Ravaud, M. Shi, V. Grünwald, 2014, Clinical Cancer Research.

Rational combination with an immunotherapy backbone in genitourinary cancers

Chia‐Chi Lin, Jhe-Cyuan Guo, 2020, Urological Science.

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

J. Shih, J. Yang, Chia‐Chi Lin, 2015, Therapeutic advances in medical oncology.

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

H. Iwata, K. Tamura, J. Watanabe, 2021, Clinical pharmacology and therapeutics.

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

J. Dancey, Helen X. Chen, A. Tolcher, 2009, Cancer Chemotherapy and Pharmacology.

Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma.

Chih-Hung Hsu, Y. Pu, Chia‐Chi Lin, 2008, Urologic oncology.

Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.

Chia‐Chi Lin, Y. Sheen, C. Chu, 2016, JAMA dermatology.

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

Chih-Hung Hsu, Chia‐Chi Lin, A. Cheng, 2006, Investigational New Drugs.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

M. Osada, K. Muro, Chia‐Chi Lin, 2021, Targeted Oncology.

Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies

G. Curigliano, A. Santoro, A. Naing, 2019, Clinical Trials.

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of Experimental & Clinical Cancer Research.

Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Lunceford, M. Ayers, R. Berger, 2016 .

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Toshio Shimizu, D. Faller, K. Yonemori, 2021, Targeted Oncology.

Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.

P. LoRusso, Yoon-Koo Kang, L. Naumovski, 2014 .

Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

R. Greil, A. Santoro, T. Yau, 2021 .

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

A. Shaw, S. Ou, Gregory Riely, 2019, The Lancet. Oncology.

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor

Chia‐Chi Lin, Y. Tseng, R. Hong, 2012, Investigational New Drugs.

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy

G. Sonpavde, W. Oh, M. Galsky, 2013, Cancer.

A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.

Y. Tsai, Chih-Hung Hsu, Y. Chiang, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).

Y. Bang, Yoon-Koo Kang, Z. Wainberg, 2018 .

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007, Urologic oncology.

Original article Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007 .

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

J. Schellens, J. Soria, Sunil Sharma, 2016 .

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

T. Seiwert, R. Mehra, L. Chow, 2018, British Journal of Cancer.

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012

Y. Bang, K. Muro, Chia‐Chi Lin, 2018, Cancer science.

Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy

Shyang-Rong Shih, Chia‐Chi Lin, Yi-Cheng Chang, 2019, Ocular immunology and inflammation.

Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).

S. Culine, M. Santis, J. Bellmunt, 2014 .

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of Clinical Oncology.

Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma

K. Yeh, Y. Tsai, Chih-Hung Hsu, 2007, Anti-cancer drugs.

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

A. Shaw, S. Peters, E. Felip, 2020, Lung cancer.

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

J. Shih, Chiun Hsu, Pan‐Chyr Yang, 2008, Lung cancer.

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2020, The oncologist.

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma

G. Sonpavde, A. Leiter, W. Oh, 2016, Bladder cancer.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

C. Chiu, Dong-Wan Kim, G. Chang, 2023, JTO clinical and research reports.

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.

P. Ascierto, R. Ramlau, L. Paz-Ares, 2018 .

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.

A. Shaw, S. Ou, E. Felip, 2017 .

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study

Chiun Hsu, C. Yen, Chia‐Chi Lin, 2020, The oncologist.

Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma

J. Blay, A. Italiano, S. Ferretti, 2018, Clinical Trials.

Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.

K. Yeh, Chih-Hung Hsu, Chia‐Chi Lin, 2013, Anticancer research.

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

R. Holcombe, G. Abou-Alfa, M. Mulcahy, 2011, Cancer Chemotherapy and Pharmacology.

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Chao-yuan Huang, Y. Pu, Chia‐Chi Lin, 2006, Biochemical pharmacology.

Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).

R. Salgia, P. LoRusso, Yoon-Koo Kang, 2015 .

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Y. Tsai, Chih-Hung Hsu, Chao-yuan Huang, 2009, International journal of radiation oncology, biology, physics.

Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.

Chih-Hung Hsu, Chia‐Chi Lin, Y. Tu, 2015, Japanese journal of clinical oncology.

Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: a two-case study.

Chih-Hung Hsu, Y. Pu, Chia‐Chi Lin, 2006, Anticancer research.

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.

E. Hitre, Chia‐Chi Lin, M. Brose, 2021 .

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

K. Tamura, J. Gilbert, S. Piha-Paul, 2019, BMC Cancer.

Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone‐producing thymic neuroendocrine neoplasm

Shyang-Rong Shih, Hsiu‐Po Wang, Chia‐Chi Lin, 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.

K. Tamura, J. Gilbert, S. Piha-Paul, 2016 .

Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

G. Sonpavde, W. Oh, M. Galsky, 2012 .

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

Chia‐Chi Lin, T. Guren, M. Shah, 2023, Cancer.

Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.

Jang-Ming Lee, Hsiu‐Po Wang, K. Yeh, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

Abstract 3725: Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells

Chia-Chi Lin, Yu-Chieh Tsai, J. Yang, 2012 .

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

N. Strelkowa, J. Yang, Chih-Hung Hsu, 2020, British Journal of Cancer.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

M. Climent, J. Bono, Chia‐Chi Lin, 2019, Journal of Clinical Oncology.

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

M. Climent, Chia‐Chi Lin, J. D. de Bono, 2023, British Journal of Cancer.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

G. Sonpavde, W. Oh, M. Galsky, 2013, Cancer.

49 – Management of Toxicities of Targeted Therapies

J. Yang, Chia‐Chi Lin, C. Chu, 2018 .

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study.

J. Blay, A. Italiano, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

RET mutations and medullary thyroid cancer.

Chia‐Chi Lin, 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.

Chia-Chi Lin, Chia‐Chi Lin, Chih-Hsin Yang, 2010, Discovery medicine.

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy

G. Sonpavde, W. Oh, M. Galsky, 2013, Cancer.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers

B. Sangro, T. Yau, Chia‐Chi Lin, 2023, Cancer Research.

Timing of multikinase inhibitor initiation in differentiated thyroid cancer

M. Schlumberger, Chia‐Chi Lin, M. Brose, 2017, Endocrine-related cancer.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

F. Izzo, M. Colombo, Sheng-Nan Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, Y. Bang, D. Juric, 2014 .

Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on Nsclc Current Treatment Options Novel Approaches Targeting Mitosis

J. Yang, Chia‐Chi Lin, Ren, 2022 .

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

C. Dooms, E. Felip, M. Schuler, 2023, Journal of Clinical Oncology.

Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma.

Yih-Leong Chang, Jang-Ming Lee, Chih-Hung Hsu, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.